A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
Status:
NOT_YET_RECRUITING
Trial end date:
2027-07-10
Target enrollment:
Participant gender:
Summary
This is a randomized double-blind, placebo-controlled, multicenter phase III clinical study evaluating the efficacy and safety of AK120 in the treatment of moderate-to-severe AD in adolescents.